Develops drugs for RAS/MAPK pathway-driven cancers.
Jun 2026Revenue $87.5M/yrExpenses $247M/yr
Expected break-even Jan 2028Cash runway ≈ 10 months from Jun 2026
Figures by year
When will Verastem be profitable?
Its revenue and expense trends are projected to cross in Jan 2028. In the 12 months to Jun 2026, revenue was $87.5M and expenses $247M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $30.9M | $201M | −$170M |
| Dec 2024 | $10.0M | $125M | −$115M |
| Dec 2022 | $2.60M | $75.5M | −$72.9M |
| Dec 2021 | $2.05M | $63.5M | −$61.4M |
| Dec 2020 | $88.5M | $138M | −$49.4M |
| Dec 2019 | $17.5M | $150M | −$132M |
| Dec 2018 | $26.7M | $122M | −$94.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.